Close this search box.

IGC Pharma Announces Equity Analyst Coverage by Recommendation and $3.00 Price Target


Potomac, MD, February 23, 2024
​-IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendiant) has issued an analyst coverage research report on the Company’s common stock.

A copy of the analyst report can be obtained directly from Ascendiant:

All reports on IGC Pharma prepared by analysts represent the views of those analysts and are not necessarily those of IGC Pharma. IGC is not responsible for the content, accuracy, or timelines provided by analysts. By referring to these analysts or distributing their opinions, IGC does not in any way commit itself to the validity of such information, conclusions, or recommendations.

What we do is essential, adressing an unmet need

Alzheimer’s disease affects millions worldwide, inflicting profound hardship on individuals and families alike. Perhaps you, like many of us, have witnessed the devastating impact of dementia firsthand. The neuropsychiatric symptoms associated with Alzheimer’s, particularly agitation and aggression, present significant challenges for patients and caregivers alike. Sadly, the available treatments are limited, with only one medication approved in recent years, albeit with serious limitations.

Alzheimer's Desease

Alzheimer’s affects over 400 million individuals across its continuum, making it the leading cause of dementia worldwide. With no cure, it affects as many as 22% of all persons aged 50 and above. It is likely that you or someone you know has been touched by this devastating disease. I invite you to join us in the fight against Alzheimer’s. Together we can make a difference.

Forward-Looking Statements:

 This press release contains forward-looking statements. These forward-looking statements are based largely on IGC Pharma’s expectations and are subject to several risks and uncertainties, certain of which are beyond IGC Pharma’s control. Actual results could differ materially from these forward-looking statements as a result of, among other factors, the Company’s failure or inability to commercialize one or more of the Company’s products or technologies, including the products or formulations described in this release, or failure to obtain regulatory approval for the products or formulations, where required, or government regulations affecting AI or the AI algorithms not working as intended or producing accurate predictions; general economic conditions that are less favorable than expected; the FDA’s general position regarding cannabis- and hemp-based products; and other factors, many of which are discussed in IGC Pharma’s U.S. Securities and Exchange Commission (“SEC”) filings. IGC Pharma incorporates by reference the human trial disclosures and Risk Factors identified in its Annual Report on Form 10-K filed with the SEC on July 7, 2023, as if fully incorporated and restated herein. Considering these risks and uncertainties, there can be no assurance that the forward-looking information contained in this release will occur.


IMS Investor Relations
Walter Frank
(203) 972-9200

Janet Vasquez
(212) 645-5498

Recent Post

Follow Us

Related Posts